TERAPI FAVIPIRAVIR PADA SUBYEK COVID-19 DERAJAT SEDANG TANPA GANGGUAN LIVER DI RS PUSAT INFEKSI PROF DR SULIANTI SAROSO

  • Hastutik Cairn Brisbane Program Studi Magister Farmasi Klinis, Fakultas Farmasi Universitas Surabaya
  • Abdul Rahem Departemen Farmasi Praktis, Fakultas Farmasi Universitas Airlangga
  • Anita Purnamayanti Laboratorium Klinis Komunitas, Fakultas Farmasi Universitas Surabaya3
  • Rosamarlina Rosamarlina UPF Paru RS Pusat Infeksi Prof. dr. Sulianti Saroso
  • Memy Aviatin Instalasi Farmasi RS Pusat Infeksi Prof. dr. Sulianti Saroso
  • Adria Rusli UPF Paru RS Pusat Infeksi Prof. dr. Sulianti Saroso
Keywords: Favipiravir, Moderate covid-19, Liver, Inpatient

Abstract

The outbreak of the corona virus which first contracted in December 2019 in Wuhan, China; Currently it has been designated by the World Health Organization (WHO) as a pandemic and is known as Corona Virus Infection Disease 2019 (Covid-19). This study aimed to describe the profile of favipiravir therapy in moderate COVID-19 inpatients without liver impairment at Prof. dr. Sulianti Saroso Infection Center Hospital. The design of this study was an observational study conducted retrospectively. All the patients in this research were received favipiravir loading dose of 1600 mg bid on the first day, and 600 mg bid starting on the day-2 of therapy.  The results of the research were 81 moderate Covid-19 inpatients without history or recent liver impairment who were hospitalized in the period October 2020 - July 2021 dominating by female gender (56%). Mode of hospital admission were self-referral to Prof. dr. Sulianti Saroso Infection Center Hospital (83%), primary care (Puskesmas) referral (12%), and other hospital referral (5%). There were no comorbidity in 74,1% of the subjects. Among 25,9% subjects with comorbidity, most of the patients suffered from hypertension (29%); hypertension, and cardiovascular disease (17%). diabetes (12%); diabetes and hypertension (12%); Asthma (12).  None of the subjects experienced increased in liver transaminases (ALT, AST), nor ALP and total bilirubin. Eighty-one patients were either cured (12%) with negative PCR test results or improved (88%) at the end of the therapy.

References

Anonim. Favipiravir. Drugbank. Tersedia dari https:// drugbank.ca-drugs-DB12466

Acosta PE. Antiviral Agents (Nonretroviral). In: Brunton LL, Danfan RH, Knollmann BJ, editors. Goodman & Gilman’s the Pharmacological Basis of Therapeutics 13th ed. New York: McGraw-Hill Company. 2018.p.1105-16.

Bicer A. Turkey develops domestic drug synthesis against virus Related news Turkey denies claim of UK. Published 2021. Accessed July 31, 2021. https://www.aa.com.tr/en/health/turkey-developsdomestic-drug-synthesis-against-virus/1874442

Bosaeed M, Alharbi A, Hussein M, et al. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19. BMJ Open. 2021;11(4). doi:10.1136/bmjopen-2020-047495

Badan POM. Fact Sheet for Health Care Providers EUA of Favipiravir for Treatment Of COVID19 Patients. Published 2020. http://pionas.pom.go.id/obat-baru/avigan-tabletsalut-selaput-200-mg

COVID-19 Provisional Counts - Weekly Updates by Select Demographic and Geographic Characteristics [Internet]. [dikutip 31 Januari 2022]. Tersedia pada: https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#SexAndAge

Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, et al.

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.Arch Virol. 2021 Mar;166(3):949-954. doi: 10.1007/s00705-021-04956-9. Epub 2021 Jan 25.

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. doi:10.5582/ddt.2020.01012

Fehr AR and Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. Methods Mol Biol. 2015; 1282:1-23.

Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Japan Acad Ser B. 2017;93(7):449-463. doi:10.2183/pjab.93.027

Fujifilm Toyama Chemical. Fujifilm announces the Start of a New Phase III Clinical Trial of Anti-influenza Drug Avigan® Tablet in Japan, Targeting COVID-19 Patients. Accessed July 29,2021. https://www.fujifilm.com/jp/en/news/hq/6478

Graselli G., et.al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICU Softhe Lombardy Region, Italy. Journal of American Medical Association, 2020;E1-8, DOI:10.1001/ jama.2020.5394

GuGuo, Y. R. et al. (2020) ‘The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status’, Military Medical Research. doi: 10.1186/s40779-020-00240-0.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.H.

Ivashchenko AA, Dmitriev KA, Vostokova N V, et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021;73(3):531-534. doi:10.1093/cid/ciaa1176

Kemenkes RI. (2020). Agustus 2020 PEDOMAN TATALAKSANA COVID-19 (Edisi kedua).

Kemenkes RI (2021). COVID-19 INDONESIA Per 16 Mei 2021. INFEKSI EMERGING. Media Informasi Resmi Terkini Penyakit Infeksi Emerging. Diakses pada https://infeksiemerging.kemkes.go.id/ dashboard/covid-19.

Marshall JC, Murthy S, Diaz J, Adhikari N, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7.

Ministry of Health, Labour, and Welfare – Japan. Report on the Deliberation Results; 2014. Available from http:// https://www.pmda.go.jp/files/000210319.pdf

Ministry of Health Russian Federation. Safety of Use Medicinal Product CORONAVIR (INN-Favipiravir).; 2020. https://roszdravnadzor.gov.ru/i/upload/images/2020/9 /1/1598959289.93821-1-147723.pdf

News F. Dr . Reddy ’ s Laboratories announces the launch of AVIGAN ® ( Favipiravir ) in India. Published 2020. Accessed July 31, 2021. https://www.businesswire.com/news/home/202008190 05246/en/Dr.-Reddys-Laboratories-announces-thelaunch-of-AVIGAN®-Favipiravir-in-India

Notoatmodjo, S. (2018). Metodologi Penelitian Kesehatan. Jakarta: Rineka Cipta

Pharma S. India’s Lupin to sell generic COVID-19 drug favipiravir. Published online 2021:8-9.

PRINCIPLE Trial. Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial. Accessed July 29, 2021. https://www.principletrial.org/news/favipiravir-to-beinvestigated-as-a-possible-covid-19-treatment-for-athome-recovery-in-the-principle-trial

Reuters. Sun Pharma latest to sell COVID-19 drug favipiravir in India. Published 2020. Accessed July 31, 2021. https://www.reuters.com/article/idUSKCN25019U

Russian Direct Investment Funds. Russian Ministry of Health approves the first COVID-19 drug Avifavir produced by JV of RDIF and ChemRar. Published 2020. Accessed July 31, 2021. https://rdif.ru/Eng_fullNews/5220/

Reuters. India’s Hetero wins approval to sell COVID-19 drug favipiravir. Published 2020. Accessed July 31, 2021. https://www.reuters.com/article/idUSKCN24U0Q0

Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020:1-8

Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049-57

WHO. (2020). Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-andthe-virus-that-causes-it

WHO. Rolling updates on coronavirus disease (COVID-19). Events as they happen. 2020

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. Vol. 323, JAMA - Journal of the American Medical Association. 2020. p. 1239–4

YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status. Military Medical Research. 2020.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.

Published
2022-10-31
How to Cite
Brisbane, H., Rahem, A., Purnamayanti, A., Rosamarlina, R., Aviatin, M., & Rusli, A. (2022). TERAPI FAVIPIRAVIR PADA SUBYEK COVID-19 DERAJAT SEDANG TANPA GANGGUAN LIVER DI RS PUSAT INFEKSI PROF DR SULIANTI SAROSO. Jurnal Ilmiah Ibnu Sina, 7(2), 261-269. https://doi.org/10.36387/jiis.v7i2.880
Section
Artikel

Most read articles by the same author(s)